Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New therapeutic options for actinic keratosis and basal cell carcinoma.

Seminars in cutaneous medicine and surgery - 1 Jun 2014

Sligh James E

Abstract excerpt

Actinic keratosis (AK) is a common premalignant skin lesion that is frequently treated by cryosurgery. Basal cell carcinoma is the most common malignancy of man, and early-stage lesions are usually cured via surgery. Advanced basal cell carcinoma may require more extensive surgery resulting in deformity, and many advanced lesions cannot be treated surgically. Several recent developments have improved therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyridines
Share to Aminoquinolines
Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Basal Cell

Share to Diterpenes

Share to Patched Receptors

Share to Receptors, Cell Surface

Share to Skin Neoplasms

Source

Identifiers

PMID: 25268601
DOI: 10.12788/j.sder.0100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New therapeutic options for actinic keratosis and basal cell carcinoma.PMID 25268601Read ↗

From actinic keratosis to cutaneous squamous cell carcinoma: the key pathogenesis and treatmentsSemantic proximity Read ↗

Clinical treatment options for early-stage and advanced conjunctival melanoma.Semantic proximity Read ↗

Update in the Management of Basal Cell Carcinoma.Semantic proximity Read ↗

Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.Semantic proximity Read ↗

A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the LiteratureSemantic proximity Read ↗

Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomasSemantic proximity Read ↗

Basal cell carcinoma — molecular biology and potential new therapiesSemantic proximity Read ↗

Towards a more specific therapy: targeting nonmelanoma skin cancer cells.Semantic proximity Read ↗

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.Semantic proximity Read ↗

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and BeyondSemantic proximity Read ↗

Increasing Mohs Micrographic Surgery Utilization in Darker Skin Phenotypes From 2011 to 2022.Semantic proximity Read ↗

Radiation sensitivity and efficacy in aggressive and non-aggressive basal cell carcinoma (BCC) of the skin: Image Guided Superficial Radiation Therapy achieves high rate of local control in sclerosing, infiltrative, morpheaform and micronodular BCC subtypes as well as in non high risk BCCs, an analysis of 7994 BCC lesionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.